(EQWL) S&P 100 Equal Weight - Overview
Etf: Equity, Technology, Healthcare, Financial, Consumer
Dividends
| Dividend Yield | 1.78% |
| Yield on Cost 5y | 3.02% |
| Yield CAGR 5y | 8.46% |
| Payout Consistency | 95.7% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 10.9% |
| Relative Tail Risk | 3.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.81 |
| Alpha | 4.18 |
| Character TTM | |
|---|---|
| Beta | 0.785 |
| Beta Downside | 0.846 |
| Drawdowns 3y | |
|---|---|
| Max DD | 14.95% |
| CAGR/Max DD | 1.21 |
Description: EQWL S&P 100 Equal Weight January 15, 2026
The Invesco S&P 100 Equal Weight ETF (EQWL) commits at least 90% of its assets to the securities that make up the S&P 100® Index, but applies an equal-weight methodology so each constituent receives the same allocation rather than being market-cap weighted.
Key metrics as of the latest filing: expense ratio ≈ 0.20%, 30-day SEC yield ≈ 2.1%, and an annualized turnover rate around 45%, reflecting the periodic rebalancing required to maintain equal weights.
Because the equal-weight design tilts exposure toward the smaller-cap members of the S&P 100, the fund is more sensitive to sector drivers such as information technology and health care, which together account for roughly 45% of the portfolio, and it tends to outperform in environments where mid-cap growth outpaces large-cap momentum.
Investors looking for a data-driven, diversified large-value exposure may want to compare EQWL’s risk-adjusted returns against traditional cap-weighted S&P 100 ETFs; a deeper quantitative breakdown is available on ValueRay for those who want to dig into the numbers.
What is the price of EQWL shares?
Over the past week, the price has changed by +1.60%, over one month by +1.90%, over three months by +7.32% and over the past year by +17.27%.
Is EQWL a buy, sell or hold?
What are the forecasts/targets for the EQWL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 144.1 | 17.4% |
EQWL Fundamental Data Overview February 02, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 2.09b USD (2.09b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 2.09b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 2.09b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 8.81% (E(2.09b)/V(2.09b) * Re(8.81%) + (debt-free company))
Discount Rate = 8.81% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)